Medical/Pharmaceuticals
EHA 2024 | Results from Five Studies of Ascentage Pharma's Key Drug Candidates Selected for Presentations at 2024 European Hematology Association Hybrid Congress
SUZHOU, China and ROCKVILLE, Md., May 15, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that the latest results from five studies have been ...
2024-05-16 09:03
1705
LoRaWAN® Temperature and Humidity Sensors for Food Safety, Pharmaceutical and Beyond
XIAMEN, China, May 15, 2024 /PRNewswire/ -- In industries like pharmaceuticals, food, and logistics, maintaining the integrity of products throughout the supply chain is critical. Temperature and humidity are two key parameters that can significantly affect the quality and safety of goods, especi...
2024-05-15 23:05
1792
Ractigen Therapeutics Receives IND Approval from China's NMPA to Initiate Phase 1 Clinical Trials for RAG-17 in SOD1-ALS Patients
SUZHOU, China, May 15, 2024 /PRNewswire/ -- Ractigen Therapeutics, a clinical-stage pharmaceutical company committed to developing pioneering therapies, today announces that the Center for Drug Evaluation (CDE) ofChina's National Medical Products Administration (NMPA) has approved the Investigat...
2024-05-15 20:00
1664
Novosis Putty Sets the Stage for U.S. Market Success with Promising Clinical Results
SEOUL, South Korea, May 14, 2024 /PRNewswire/ -- CGBio, a leading medical device company, announced a significant clinical results demonstrating a 100% interbody fusion success rate at 52 weeks for its innovative bone substitutes, "Novosis" and "Excelos Inject," which have been published in the '...
2024-05-14 20:00
1725
Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer
SHANGHAI, May 13, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical study of its novel Nectin-4-targeting ADC (R&D code: 9MW2821) for triple-negative breast cancer. Based on 9MW2821's curren...
2024-05-13 22:00
1793
ObeEnd - Pioneering Drug-Free Weight Management Wristband
VANCOUVER, BC, May 13, 2024 /PRNewswire/ -- WAT Medical, a leader in innovative healthcare solutions, announces the development of ObeEnd, the world's first weight management wristband backed by clinical evidence showcasing its efficacy in reducing dietary intake. Findings from this groundbreakin...
2024-05-13 21:00
1494
Caliway to Present the Latest Clinical Advancements at 2024 BIO International Convention
NEW TAIPEI CITY, May 11, 2024 /PRNewswire/ -- Caliway Biopharmaceuticals (Caliway) is pleased to announce its participation to share the latest clinical advancements at the upcoming 2024 BIO International Convention onWednesday, June 5th, at 11:45 a.m. PDT. The presentation will take place in Com...
2024-05-11 15:14
3297
Single-Cell Multi-Omics Analysis of IASO Bio's Equecabtagene Autoleucel in the Treatment of Autoimmune Diseases of the Central Nervous System Published in Science Immunology
SHANGHAI, NANJING, China, and SAN JOSE, Calif., May 10, 2024 /PRNewswire/ -- On May 10, 2024, the impactful international academic journal, Science Immunology, a sub-journal ofScience, published a research paper titled "Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central...
2024-05-11 10:16
4308
China Jo-Jo Drugstores Announces $2.74 Million Registered Direct Offering
HANGZHOU, China, May 10, 2024 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (Nasdaq: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider inChina, today announced that it ha...
2024-05-10 21:20
5652
Kexing Biopharm Facility Passes EU GMP Certification for Paclitaxel for Injection (Albumin Bound)
SHENZHEN, China, May 10, 2024 /PRNewswire/ -- On the evening of May 5, Kexing Biopharm (stock code: 688136) announced it had obtained a "Certificate of GMP Compliance of a Manufacturer" granted by the Norwegian Medical Products Agency in accordance with the European Medicines Agency (EMA) regulat...
2024-05-10 20:07
2314
Ribobay Pharma boosts CRDMO offerings with Cytiva's first FlexFactory platform for oligonucleotides
* FlexFactory platform for oligonucleotides, an integrated solution to boost efficiency and speed of pharmaceutical manufacturing to meet market demand SHANGHAI, May 10, 2024 /PRNewswire/ -- Ribobay Pharma, a leading Chinese biopharmaceutical contract research, development, and manufacturing o...
2024-05-10 18:39
2217
WestGene's mRNA Therapeutic Cancer Vaccine Receives FDA Approval
CHENGDU, China, May 10, 2024 /PRNewswire/ -- WestGene, a biotech company dedicated to mRNA technology, announces a historic milestone with the FDA IND approval of its mRNA therapeutic cancer vaccine, WGc-043. This landmark achievement marks the world's first approval of an EB virus-related mRNA ...
2024-05-10 12:16
1882
SN Bioscience Receives FDA Fast Track Designation for Small Cell Lung Cancer
SEOUL, South Korea, May 9, 2024 /PRNewswire/ -- SN Bioscience Co. Ltd. (CEO Park Young-hwan) announced on May 7 that the FDA has granted Fast Track Designation for small cell lung cancer (SCLC) for SNB-101 (API: SN-38), a new drug for polymer nanoparticle anticancer under clinical trial. SNB-101 ...
2024-05-10 12:00
1461
Celltrion USA's adalimumab-aaty biosimilar to HUMIRA® now available at low wholesale acquisition cost
* Adalimumab-aaty will be priced at an 85% discount to HUMIRA® (adalimumab) * Branded and unbranded versions of Celltrion USA's adalimumab biosimilar help provide more affordable options for patients JERSEY CITY, N.J., May 9, 2024 /PRNewswire/ -- CelltrionUSA announced today that adalimumab-aa...
2024-05-10 07:41
1369
FDA Clears the Individualized Nomogram for Rika Plasma Donation System
The latest innovation is anticipated to increase collection volume without increasing collection time * Rika's individualized nomogram, iNomi, can enable plasma donors to donate the right amount of plasma on any given day based on height, weight and hematocrit. * The Rika Plasma Donation Sys...
2024-05-09 20:00
1374
Infinitopes' Article in Peer-Reviewed Journal Seeks to Unlock the Potential of Cancer Vaccines
Publication in Human Vaccines and Immunotherapeutics highlights progress in understanding tumour biology and vaccine technologies since the pandemic OXFORD, England, May 9, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in pr...
2024-05-09 15:30
2028
Formosa Pharmaceuticals Announces Licensing Agreement with Tabuk Pharmaceuticals, for Commercialization of Clobetasol Propionate Ophthalmic Suspension for the Treatment of Inflammation and Pain Following Ocular Surgery
TAIPEI, May 9, 2024 /PRNewswire/ -- Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TWO) announced today that the company has entered into an exclusive licensing agreement with Tabuk Pharmaceuticals Manufacturing Company ("Tabuk"), for exclusive rights to the commercialization of clobetasol...
2024-05-09 15:00
2092
NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia
SHANGHAI and LEXINGTON, Mass. , May 8, 2024 /PRNewswire/ -- NeuShen Therapeutics (the "Company"), a clinical-stage global biotechnology company dedicated to pioneering treatments for neurological and psychiatric disorders, today announced the dosing of the first healthy volunteer inAustralia in t...
2024-05-08 21:00
1470
TiumBio Announces Positive Topline Data from Phase 2a Trial of Merigolix in Patients with Moderate to Severe Endometriosis-Associated Pain
* The study (NCT05138562) met its primary endpoint of change of dysmenorrhea (menstrual pain) score from baseline to 12 weeks compared to placebo across all tested doses (120 mg, 240 mg, and 320 mg) * Merigolix is expected to emerge as a best-in-class treatment based on its excellent pain re...
2024-05-08 20:00
1237
Minghui Pharmaceutical to Present the Phase I/II Study of MHB088C (B7-H3 ADC) for the Treatment of Patients with Recurrent or Metastatic Solid Tumors in Late-breaking Oral Presentation at the 2024 ASCO Annual Meeting
SHANGHAI, May 8, 2024 /PRNewswire/ -- Minghui Pharmaceutical, Inc., a late-stage clinical biopharmaceutical company focused on autoimmune diseases and oncology, will feature Dr.Lin Shen from Beijing Cancer Hospital at the upcoming ASCO Annual Meeting inChicago. Dr. Shen will present the results f...
2024-05-08 18:18
6481
Week's Top Stories
Most Reposted
Rocket Travel by Agoda Shares Revealing New Report and Showcases Solution to Transform Hotel Distribution
[Picked up by 313 media titles]
2024-11-21 10:30Rockwell Automation and Microsoft Deliver on a Shared Vision to Accelerate Industrial Transformation
[Picked up by 308 media titles]
2024-11-20 13:29Durabook and Parent Company, Twinhead International Corp., Celebrate 40 Years of Innovation in Computing Solutions
[Picked up by 301 media titles]
2024-11-20 16:30
Travel loyalty programs to focus on offering personalized and flexible customer experiences in 2025
[Picked up by 298 media titles]
2024-11-19 10:42Philips and Edith Cowan University Australia Collaborate to Equip the Next Generation of Healthcare Professionals to leverage new technologies
[Picked up by 284 media titles]
2024-11-20 09:00
Most Read
Strategic Forum in Chongqing Drives Expansion of New Western Land-Sea Corridor
2024-11-16 14:15
5203
